Trial result ·
Native collagen matrix plus PHMB antimicrobial in hard-to-heal diabetic foot ulcers: results from the PREPARE randomised controlled trial.
Written based on 1 research study on PubMed, searched on 5 Nov 2026.
What was studied
This trial tested a collagen wound matrix with an antimicrobial in diabetic foot ulcers. The product is called PCMP. It was given with standard care. The comparison group got standard care alone. The ulcers were hard to heal. The trial ran at 25 US sites. 170 patients were randomised. 96 got PCMP plus standard care. 74 got standard care alone. The main outcome was complete wound closure within 12 weeks.
What they found
More patients had complete closure with PCMP plus standard care. The difference was significant, with p=0.047. Mean wound area reduction was greater with PCMP. It was 75.23 against 58.06. No adverse events or serious events were attributed to PCMP.
What it means for patients
The authors say PCMP plus standard care improved closure at 12 weeks. They say this supports its use as an add-on antimicrobial barrier for these wounds.
Why it is not certain yet
The confidence range reached almost no difference. The groups were unequal in size. Patients whose wounds shrank a lot during screening were left out. The abstract reports 12-week results only.
Source
Native collagen matrix plus PHMB antimicrobial in hard-to-heal diabetic foot ulcers: results from the PREPARE randomised controlled trial.
PubMed · PMID 42842703We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Type 2 diabetes publications